Duration of Reduced CA19-9 Levels Is a Better Prognostic Factor Than Its Rate of Reduction for Unresectable Locally Advanced Pancreatic Cancer
Abstract
:Simple Summary
Abstract
1. Introduction
2. Materials and Methods
2.1. Serum Levels of CA 19-9
2.2. Patients
2.3. Resectability and Treatment
2.4. Statistical Analysis
3. Results
3.1. Patient Characteristics
3.2. CA19-9 Reduction Rate and Survival
3.3. CA19-9 Reduction Duration and Overall Survival or Metastasis
3.4. Factors Related to Long-Term Survival
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2020. CA Cancer J. Clin. 2020, 70, 7–30. [Google Scholar] [CrossRef] [PubMed]
- Wolfgang, C.L.; Herman, J.M.; Laheru, D.A.; Klein, A.P.; Erdek, M.A.; Fishman, E.K.; Hruban, R.H. Recent progress in pancreatic cancer. CA Cancer J. Clin. 2013, 63, 318–348. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yoo, C.; Shin, S.H.; Kim, K.P.; Jeong, J.H.; Chang, H.M.; Kang, J.H.; Lee, S.S.; Park, D.H.; Song, T.J.; Seo, D.W.; et al. Clinical Outcomes of Conversion Surgery after Neoadjuvant Chemotherapy in Patients with Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer: A Single-Center, Retrospective Analysis. Cancers 2019, 11, 278. [Google Scholar] [CrossRef] [Green Version]
- Jang, J.Y.; Han, Y.; Lee, H.; Kim, S.W.; Kwon, W.; Lee, K.H.; Oh, D.Y.; Chie, E.K.; Lee, J.M.; Heo, J.S.; et al. Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer: A Prospective, Randomized, Open-label, Multicenter Phase 2/3 Trial. Ann. Surg. 2018, 268, 215–222. [Google Scholar] [CrossRef] [PubMed]
- Hackert, T.; Ulrich, A.; Büchler, M.W. Borderline resectable pancreatic cancer. Cancer Lett. 2016, 375, 231–237. [Google Scholar] [CrossRef]
- Satoi, S.; Yamaue, H.; Kato, K.; Takahashi, S.; Hirono, S.; Takeda, S.; Eguchi, H.; Sho, M.; Wada, K.; Shinchi, H.; et al. Role of adjuvant surgery for patients with initially unresectable pancreatic cancer with a long-term favorable response to non-surgical anti-cancer treatments: Results of a project study for pancreatic surgery by the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J. Hepato-Biliary-Pancreat. Sci. 2013, 20, 590–600. [Google Scholar] [CrossRef]
- Rose, J.B.; Rocha, F.G.; Alseidi, A.; Biehl, T.; Moonka, R.; Ryan, J.A.; Lin, B.; Picozzi, V.; Helton, S. Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival. Ann. Surg. Oncol. 2014, 21, 1530–1537. [Google Scholar] [CrossRef]
- Wolfe, A.R.; Prabhakar, D.; Yildiz, V.O.; Cloyd, J.M.; Dillhoff, M.; Abushahin, L.; Alexandra Diaz, D.; Miller, E.D.; Chen, W.; Frankel, W.L.; et al. Neoadjuvant-modified FOLFIRINOX vs. nab-paclitaxel plus gemcitabine for borderline resectable or locally advanced pancreatic cancer patients who achieved surgical resection. Cancer Med. 2020, 9, 4711–4723. [Google Scholar] [CrossRef]
- Tsujimoto, A.; Sudo, K.; Nakamura, K.; Kita, E.; Hara, R.; Takayama, W.; Ishii, H.; Yamaguchi, T. Gemcitabine plus nab-paclitaxel for locally advanced or borderline resectable pancreatic cancer. Sci. Rep. 2019, 9, 16187. [Google Scholar] [CrossRef] [Green Version]
- Lee, W.; Park, Y.; Kwon, J.W.; Jun, E.; Song, K.B.; Lee, J.H.; Hwang, D.W.; Yoo, C.; Kim, K.P.; Jeong, J.H.; et al. Reduced and Normalized Carbohydrate Antigen 19-9 Concentrations after Neoadjuvant Chemotherapy Have Comparable Prognostic Performance in Patients with Borderline Resectable and Locally Advanced Pancreatic Cancer. J. Clin. Med. 2020, 9, 1477. [Google Scholar] [CrossRef] [PubMed]
- Boeck, S.; Stieber, P.; Holdenrieder, S.; Wilkowski, R.; Heinemann, V. Prognostic and therapeutic significance of carbohydrate antigen 19-9 as tumor marker in patients with pancreatic cancer. Oncology 2006, 70, 255–264. [Google Scholar] [CrossRef] [Green Version]
- Boone, B.A.; Steve, J.; Zenati, M.S.; Hogg, M.E.; Singhi, A.D.; Bartlett, D.L.; Zureikat, A.H.; Bahary, N.; Zeh, H.J., 3rd. Serum CA 19-9 response to neoadjuvant therapy is associated with outcome in pancreatic adenocarcinoma. Ann. Surg. Oncol. 2014, 21, 4351–4358. [Google Scholar] [CrossRef] [PubMed]
- Tzeng, C.W.; Balachandran, A.; Ahmad, M.; Lee, J.E.; Krishnan, S.; Wang, H.; Crane, C.H.; Wolff, R.A.; Varadhachary, G.R.; Pisters, P.W.; et al. Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer. HPB 2014, 16, 430–438. [Google Scholar] [CrossRef] [Green Version]
- Groot, V.P.; Gemenetzis, G.; Blair, A.B.; Rivero-Soto, R.J.; Yu, J.; Javed, A.A.; Burkhart, R.A.; Rinkes, I.; Molenaar, I.Q.; Cameron, J.L.; et al. Defining and Predicting Early Recurrence in 957 Patients With Resected Pancreatic Ductal Adenocarcinoma. Ann. Surg. 2019, 269, 1154–1162. [Google Scholar] [CrossRef]
- Klaiber, U.; Schnaidt, E.S.; Hinz, U.; Gaida, M.M.; Heger, U.; Hank, T.; Strobel, O.; Neoptolemos, J.P.; Mihaljevic, A.L.; Büchler, M.W.; et al. Prognostic Factors of Survival After Neoadjuvant Treatment and Resection for Initially Unresectable Pancreatic Cancer. Ann. Surg. 2021, 273, 154–162. [Google Scholar] [CrossRef]
- Chung, K.H.; Ryu, J.K.; Lee, B.S.; Jang, D.K.; Lee, S.H.; Kim, Y.T. Early decrement of serum carbohydrate antigen 19-9 predicts favorable outcome in advanced pancreatic cancer. J. Gastroenterol. Hepatol. 2016, 31, 506–512. [Google Scholar] [CrossRef]
- Nakai, Y.; Kawabe, T.; Isayama, H.; Sasaki, T.; Yagioka, H.; Yashima, Y.; Kogure, H.; Arizumi, T.; Togawa, O.; Ito, Y.; et al. CA 19-9 response as an early indicator of the effectiveness of gemcitabine in patients with advanced pancreatic cancer. Oncology 2008, 75, 120–126. [Google Scholar] [CrossRef]
- Hess, V.; Glimelius, B.; Grawe, P.; Dietrich, D.; Bodoky, G.; Ruhstaller, T.; Bajetta, E.; Saletti, P.; Figer, A.; Scheithauer, W.; et al. CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial. Lancet. Oncol. 2008, 9, 132–138. [Google Scholar] [CrossRef]
- Reni, M.; Peretti, U.; Zanon, S.; Macchini, M.; Balzano, G.; Mazza, E.; Tamburrino, D.; Orsi, G.; Arcidiacono, P.G.; Falconi, M.; et al. Time to CA19-9 nadir: A clue for defining optimal treatment duration in patients with resectable pancreatic ductal adenocarcinoma. Cancer Chemother. Pharmacol. 2020, 85, 641–650. [Google Scholar] [CrossRef]
- Tempero, M.A.; Uchida, E.; Takasaki, H.; Burnett, D.A.; Steplewski, Z.; Pour, P.M. Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer. Cancer Res. 1987, 47, 5501–5503. [Google Scholar]
- Tempero, M.A.; Malafa, M.P.; Al-Hawary, M.; Asbun, H.; Bain, A.; Behrman, S.W.; Benson, A.B., 3rd; Binder, E.; Cardin, D.B.; Cha, C.; et al. Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Canc. Netw. 2017, 15, 1028–1061. [Google Scholar] [CrossRef] [PubMed]
- Eisenhauer, E.A.; Therasse, P.; Bogaerts, J.; Schwartz, L.H.; Sargent, D.; Ford, R.; Dancey, J.; Arbuck, S.; Gwyther, S.; Mooney, M.; et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur. J. Cancer 2009, 45, 228–247. [Google Scholar] [CrossRef] [PubMed]
- Aldakkak, M.; Christians, K.K.; Krepline, A.N.; George, B.; Ritch, P.S.; Erickson, B.A.; Johnston, F.M.; Evans, D.B.; Tsai, S. Pre-treatment carbohydrate antigen 19-9 does not predict the response to neoadjuvant therapy in patients with localized pancreatic cancer. HPB 2015, 17, 942–952. [Google Scholar] [CrossRef] [Green Version]
- Truty, M.J.; Kendrick, M.L.; Nagorney, D.M.; Smoot, R.L.; Cleary, S.P.; Graham, R.P.; Goenka, A.H.; Hallemeier, C.L.; Haddock, M.G.; Harmsen, W.S.; et al. Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer. Ann. Surg. 2021, 273, 341–349. [Google Scholar] [CrossRef]
- Rose, J.B.; Edwards, A.M.; Rocha, F.G.; Clark, C.; Alseidi, A.A.; Biehl, T.R.; Lin, B.S.; Picozzi, V.J.; Helton, W.S. Sustained Carbohydrate Antigen 19-9 Response to Neoadjuvant Chemotherapy in Borderline Resectable Pancreatic Cancer Predicts Progression and Survival. Oncologist 2020, 25, 859–866. [Google Scholar] [CrossRef] [Green Version]
- Lopez, N.E.; Prendergast, C.; Lowy, A.M. Borderline resectable pancreatic cancer: Definitions and management. World J. Gastroenterol. 2014, 20, 10740–10751. [Google Scholar] [CrossRef] [PubMed]
- Hamada, C.; Okusaka, T.; Ikari, T.; Isayama, H.; Furuse, J.; Ishii, H.; Nakai, Y.; Imai, S.; Okamura, S. Efficacy and safety of gemcitabine plus S-1 in pancreatic cancer: A pooled analysis of individual patient data. Br. J. Cancer 2017, 116, 1544–1550. [Google Scholar] [CrossRef]
- Chen, Y.; Sun, X.J.; Jiang, T.H.; Mao, A.W. Combined radiochemotherapy in patients with locally advanced pancreatic cancer: A meta-analysis. World J. Gastroenterol. 2013, 19, 7461–7471. [Google Scholar] [CrossRef]
- Sudo, K.; Yamaguchi, T.; Ishihara, T.; Nakamura, K.; Hara, T.; Denda, T.; Tawada, K.; Imagumbai, T.; Araki, H.; Sakai, M.; et al. Phase II study of oral S-1 and concurrent radiotherapy in patients with unresectable locally advanced pancreatic cancer. Int. J. Radiat. Oncol. Biol. Phys. 2011, 80, 119–125. [Google Scholar] [CrossRef]
- Okusaka, T.; Ito, Y.; Ueno, H.; Ikeda, M.; Takezako, Y.; Morizane, C.; Kagami, Y.; Ikeda, H. Phase II study of radiotherapy combined with gemcitabine for locally advanced pancreatic cancer. Br. J. Cancer 2004, 91, 673–677. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Factors | n (%) | Median (Range) |
---|---|---|
Age, years | 68 (36–87) | |
Sex, female/male | 32 (41)/47 (59) | |
PS, 0/1,2 | 63 (80)/16 (20) | |
Pre-CA19-9, U/mL, | 182 (10–21084) | |
Location, Head/Body-tail | 41 (52)/38 (48) | |
Tumor size, mm | 32 (12–64) | |
Resectability, BR/LA | 22 (28)/57 (72) | |
Invasion, (CA/SMA/CHA/PV) | 35 (44)/36 (45)/3 (4)/5 (7) | |
1st Treatment, CTx/CRTx | 63 (80)/16 (20) | |
CTx regimen | GnP 41, Gem 13, GS 4, S1 3, FFX 2 | |
CRTx regimen | Gem + S1 + RT | |
PFS, month | 8 (3–74) | |
OS, month | 17 (4–128) |
Variable | Univariate Analysis | Multivariate Analysis | |||||
---|---|---|---|---|---|---|---|
LS (n = 22) | not LS (n = 57) | p Value | Odds Ratio | 95% CI | p Value | ||
Age (year) | 0.80 | ||||||
≥65/<65 | 14/8 | 38/19 | |||||
Gender | 0.30 | ||||||
Male/Female | 15/7 | 32/25 | |||||
Performance status | 0.07 | 0.35 | 0.07–1.81 | 0.21 | |||
≥1/0 | 2/20 | 16/41 | |||||
Location | 0.80 | ||||||
Head/Body-Tail | 12/10 | 29/28 | |||||
Tumor Size (cm) | 0.80 | ||||||
≥3/<3 | 14/8 | 35/22 | |||||
Initial Resectability | 0.9 | ||||||
BR/LA | 6/16 | 16/41 | |||||
Treatment | 0.03 | 2.63 | 0.83–8.26 | 0.09 | |||
CRTx/CTx | 10/12 | 12/45 | |||||
CA19-9 | |||||||
Initial level | 1.00 | ||||||
≥37/<37 | 18/4 | 45/12 | |||||
Reduction cases | 0.09 | ||||||
≥1/<1 | 0/22 | 8/49 | |||||
Duration of 44% reduction | <0.01 | 5.75 | 1.47–22.36 | 0.01 | |||
≥3 m/Others | 19/3 | 29/28 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Tomishima, K.; Ishii, S.; Fujisawa, T.; Ikemura, M.; Ota, H.; Kabemura, D.; Ushio, M.; Fukuma, T.; Takahashi, S.; Yamagata, W.; et al. Duration of Reduced CA19-9 Levels Is a Better Prognostic Factor Than Its Rate of Reduction for Unresectable Locally Advanced Pancreatic Cancer. Cancers 2021, 13, 4224. https://doi.org/10.3390/cancers13164224
Tomishima K, Ishii S, Fujisawa T, Ikemura M, Ota H, Kabemura D, Ushio M, Fukuma T, Takahashi S, Yamagata W, et al. Duration of Reduced CA19-9 Levels Is a Better Prognostic Factor Than Its Rate of Reduction for Unresectable Locally Advanced Pancreatic Cancer. Cancers. 2021; 13(16):4224. https://doi.org/10.3390/cancers13164224
Chicago/Turabian StyleTomishima, Ko, Shigeto Ishii, Toshio Fujisawa, Muneo Ikemura, Hiroto Ota, Daishi Kabemura, Mako Ushio, Taito Fukuma, Sho Takahashi, Wataru Yamagata, and et al. 2021. "Duration of Reduced CA19-9 Levels Is a Better Prognostic Factor Than Its Rate of Reduction for Unresectable Locally Advanced Pancreatic Cancer" Cancers 13, no. 16: 4224. https://doi.org/10.3390/cancers13164224